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ments. ConClusions: The body of literature from this 5-year period provides con-
tinued evidence of the benefits of a pharmacist within a PCMH to patients and 
health systems. This reemphasizes the need for future pharmacists to assume a 
greater role on the health care teams within PCMHs.
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objeCtives: There is strong evidence that health management programs should 
be designed according to the need of a target population. Personalized medicine is 
currently a popular topic in health care debates, yet the basic differentiation into 
females and males is hardly found in programs of health insurances. This explora-
tive study aims at elucidating the opinion of German Statutory Health Insurance 
(SHI) managers on gender-specific care, to understand responsibilities and possible 
implementation opportunities. Methods: A questionnaire on the implementation 
of gender medicine in current health care landscape, based on literature review 
and expert consultations, was developed from April to June 2013. It includes open- 
and closed-ended questions on the following three topics: expectations/prioritiza-
tion, need for action and implementation. Forty-eight insurance managers of the 
largest German SHIs, covering over 95% of the market, were asked to complete a 
web-based survey, achieving a response rate of 57%. Descriptive analyses and intra-
group comparisons have been performed to assess statistical differences. Results: 
According to the insurance managers (76%), gender-specific care is not sufficiently 
incorporated into standard medical care. Respondents claim the responsibility lies 
with doctors and with their associations. Only 30% of respondents see an active 
contribution of health insurances as a prerequisite for a successful implementation 
of gender-specific care. The key success factors, according to insurance managers 
are: knowledge and acceptance by physicians, sufficient medical evidence, and 
the integration of gender aspects in treatment guidelines. ConClusions: German 
SHIs expect a significant governmental influence and/or support of self-governing 
bodies to achieve an incorporation of gender medicine in daily practice. In fact, 
they display a strong averseness to take primary responsibility for the integration 
of gender-specific approaches in their programs. Although insurance companies 
consider themselves only a subordinated instance, their positive perception of the 
topic should be integrated into the implementation process, as soon as critical 
hurdles in the medical field will be removed.
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objeCtives: Retina specialists currently have a choice of several effective anti-VEGF 
medications to treat neovascular age-related macular degeneration (AMD). However, 
these medications vary in price, sustainability and (more controversially) safety and 
efficacy. This study examines the treatment pattern of 2 of the most commonly used 
drugs. Methods: This was a longitudinal evaluation of the treatment patterns for 
Medicare beneficiaries who received an anti-VEGF injection for AMD. We used the 
5% Part B and Outpatient Standard Analytical Files to evaluate intravitreal treatment 
of AMD along with a determination of the number of ophthalmologist specialists. 
Results were subdivided according to the type of anti-VEGF received: bevacizumab, 
ranibizumab or the combination of the two. Results: There were a total of 4,851 
beneficiaries evaluated with an average age in excess of 80 years. Most were female 
and almost all were white. Over a three-year period, there were an average of 15 
claims per patient. Patients that were treated with bevacizumab had the fewest 
claims over the three-year period (n= 11) compared to patients that were treated 
with ranibizumab (n= 15) or a combination of bevacizumab and ranibizumab (n= 20). 
Most patients remained in the cohort for the entire 36 months of follow-up. The 
median number of ophthalmologists seen per patient was about the same for the 
three drug groups. More subjects are seen by two ophthalmologists, but received 
their drug injections from only a single individual. By contrast, when two physi-
cians were involved, the number of drug claims was higher. Non-drug claims are 
higher as well. ConClusions: This study shows the differences in the pattern 
of bevacizumab and ranibizumab use. These differences may be associated with 
socioeconomic factors and/or with disease physiology. The understanding of these 
selective utilization patterns may have major implications on health care policies.
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objeCtives: To assess the effect of a cost-management component in a Medicare 
Part D MTM administrator-implemented program on total prescription drug costs 
over 3 years. Methods: The Targeted Intervention Program (TIP) monitors prescrip-
tion claims data to identify opportunities for cost saving and care improvement, 
and then periodically generates an electronic TIP-record that notifies the patient’s 
pharmacy of the situation. Pharmacists may successfully complete the TIP-record 
action (e.g. delivering a targeted medication review), return the TIP-record with-
out completion (e.g. lack of patient or provider cooperation), or ignore it. A cohort 
of Medicare Part D beneficiaries (N = 16,180) from two drug plans participated in 
the cost-management component of this program. Their TIP records from 2010 to 
2012 were analyzed using SAS. Total prescription drug cost, averaged over 3-month 
period in order to smooth the sporadic nature of prescription fills, was modeled 
as a function of the cumulative number of generated, returned, and successful 
objeCtives: Assessment was carried out to determine perceived health service 
leadership and management skills, competencies and ability possessed by health 
care managers working in level 3, 4 and 5 hospitals. Methods: Cluster sampling 
method was used where list of counties in Nyanza was compiled in November 
2013; three out of six counties were randomly selected, 8 hospitals and 2 county 
health offices purposively selected. Thirty two health care professionals at man-
agement positions were selected for assessment using self administered question-
naire. Information was collected on perception of skills, competencies, ability and 
knowledge possessed on pre-selected 24 leadership and management aspects. A 
five step Likert rating scale was used. SPSS computer program was used to analyze 
data and results presented in percentages, graphs and tables. Results: Assessment 
showed that all respondents perceived themselves to be fair, poor or very poor in at 
least 70% of 24 management and leadership skills and competency aspects. Forty 
seven percent had never attended any training on health service management and 
leadership before. Forty one percent of those who had attended similar training 
only attended once and training period was “too brief”. Ninety one percent said 
the training be sandwiched with international exposure of whom 66% were willing 
to raise own air ticket and accommodation. Leadership, financial, management of 
health care resources, ISO certification and communication skills were identified 
as top priority gaps health managers required urgent training. Forty one percent 
said the training will help them improve on quality of health care provided in their 
hospitals. ConClusions: The assessment concluded that majority of health care 
managers have not been adequately prepared to handle health service manage-
ment and leadership roles. Therefore ,there is need to equip them with these skills 
in order to be able to handle critical leadership challenges they face in their day to 
day professional experience.
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objeCtives: To evaluate the clinical impact of a pilot integrated care manage-
ment program consisting of nurses and pharmacists to provide medication review 
and consults over the phone to commercially insured members who were recently 
discharged from the hospital (Transitional Case Management or TCM group) or 
referred from nurses (Non-TCM group). Methods: A prospective cohort analysis 
was performed using pharmacy and medical claims data. Intervention members 
who participated in the pilot between 6/18/2012 and 6/14/2013 were matched to 
control members who did not participate in the pilot on a 1:1 basis using propen-
sity score matching. The propensity score model included member demograph-
ics, baseline health indicators, previous health care utilization, and other member 
characteristics. Continuous eligibility for at least 120 days before and 30 days after 
the intervention date was required. Outcomes included hospital or emergency room 
(ER) visits within 30 days, and resolution of drug issues, such as drug-drug inter-
actions (DDIs) and non-adherence, within 120 days of the intervention date. All 
outcomes were evaluated using logistic multivariable regression models. Results: 
A total of 274 TCM intervention members and 156 Non-TCM intervention mem-
bers were included in the analysis. After propensity matching, differences between 
the intervention and control groups were no longer statistically significant. TCM 
intervention members were significantly more likely than TCM control members 
to resolve at least one drug-related issue [odds ratio (OR)= 2.18 (95% CI: 1.47, 3.22)]. 
Specifically, the odds of resolving major/contraindicated DDIs were 42% higher 
among intervention members compared to controls [OR= 1.42 (1.01, 2.00)]. Similarly, 
major/contraindicated DDIs among Non-TCM intervention members were more 
likely to be resolved than Non-TCM control members [OR= 1.89 (1.12, 3.18)]. No 
significant differences were found in terms of hospital or ER visits for TCM and 
Non-TCM groups. ConClusions: A successful collaboration between pharmacists 
and nurses significantly improved the resolution of drug-related issues in a com-
mercial population.
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objeCtives: The primary aim was to describe the various patient centered medical 
home (PCMH) models and discuss the roles for pharmacists. A secondary aim was to 
discuss implementation strategies and potential barriers. Methods: A literature 
search accessed articles published from 2008 to 2013 through electronic databases 
PubMed, pharmacy association websites, and the Agency for Healthcare Research 
and Quality website. Key terms utilized in the search were “PCMH” and “pharma-
cists.” Articles without a description of a PCMH model were excluded. The refer-
ence list of each article was searched for additional related articles. Results were 
summarized in a table, which included the year of publication, author, title, study 
design, source and findings. Results: Thirty-one articles were included in this 
review with subtopics; role of the pharmacist, implementation strategies and bar-
riers. Literature review suggests that while pharmacists can make positive impacts 
both financially and in patient outcomes, the current system and infrastructure 
may make support of a pharmacist difficult. Significant changes in a PCMH model 
must be integrated for pharmacist participation. Specifically, a pharmacist’s scope 
of practice should be established. Major themes included pharmacist collaboration 
with other health professionals, the provision of medication therapy management 
services, and chronic disease management. Implementation strategies that proved 
to be successful were consistent in allowing for open communication between 
the pharmacist and the team, a clearly defined structure for reimbursement, and 
taking an active role in monitoring or quality improvements. Barriers are related 
to reimbursement, health information technology and collaborative practice agree-
